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1. Introduction
Cancer is one of the most serious diseases around the world and it is the third leading cause
of death, exceeded only by heart and infectious diseases [1]. There are five major steps for
cancer development: initiation, promotion, malignant conversion, progression, and metastasis
[2]. Cancer is result of process, where somatic cells mutate and escape the controlled balance
of gene expression and cellular networks that maintain cellular homeostasis, which normally
prevent unwanted expansion. Perturbations in these pathways results in cellular transforma‐
tion, where cancer cells differ from their normal counterparts in many characteristics, as is loss
of differentiation, increased invasiveness, and decreased drug sensitivity [3-4]. There are six
primary hallmarks of cancer: unlimited cell proliferation, autonomous growth without the
need of external signals, resistance to growth inhibitory signals, escape from apoptosis the
ability to recruit new vasculature and increased tissue invasion and metastasis [5]. The
formation of cancer is therefore fundamentally genetic and epigenetic disease requiring
accumulation of genomic alterations to inactivate tumour suppressor and activate proto-
oncogenes [6]. These results in combined interaction of both tumour suppressors, that are not
able to inhibit tumour development and protect cells against mutation that initiate transfor‐
mation, and cancer inducers, which promotes cancer development as initiators of cellular
transformation. When cells exhibit abnormal growth and loss of apoptosis, it usually results
in cancer formation [2].
Genetic studies have revealed the mutational and epigenetic alterations of protein-coding
genes that control DNA damage response, growth arrest, cell survival and apoptotic pathways
[4]. Until recent years ago, the central dogma of molecular biology was that genetic information
is stored in protein-coding genes with RNA as an intermediate between DNA sequence and
its encoded protein [7]. Recent studies suggest that advanced stages of cancer are possessing
more severe molecular perturbations and that this could be due to function of non-coding
RNAs (ncRNAs), which were previously known only to have infrastructural functions (as
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ribosomal RNA, transfer RNA, small nuclear and nucleolar RNA). Eukaryotic genomes are
extensively transcribed into thousands of long and short ncRNAs, which are group of
endogenous RNAs that also function as regulators of gene expression. They are involved in
developmental, physiological as well as pathological processes [7,8].
However, in this review, the following characteristics of ncRNA in human cancers will be
summarized: (i) the current understanding of the critical role that lncRNAs and miRNAs may
play in cancer as tumour suppressors; (ii) outline current knowledge about some specific
lncRNA and miRNAs and their target genes in cancer; (iii) highlight their potential as bio‐
markers for patho-histological subtype classification; and (iv) highlight their potential as
biomarkers and as circulating biomarkers and therapeutic targets in cancer.
Since the majority of research regarding regulatory ncRNAs as tumour suppressor was
performed on miRNAs and in lesser extend on lncRNAs/lincRNAs, will this review further
focused on these two groups of ncRNAs.
2. Brief overview of non-coding RNAs (ncRNAs)
Classification
Of transcribed eukaryotic genomes, only 1-2 % encode for proteins, whereas the vast majority
are ncRNAs that are in more or less functional transcripts. The regulatory ncRNAs are
important regulators of gene expression in many eukaryotes and are involved in a wide range
of functions in eukaryotic biology [8,9].
Based on their function, ncRNAs can be divided into two groups. First is infrastructural group,
with ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), small nuclear RNAs (snRNAs) and
small nucleolar RNAs (snoRNAs). Second is regulatory group, with microRNAs (miRNAs),
piwi-interacting RNAs (piRNAs), small-interfering RNAs (siRNAs), long non-coding RNAs
(lncRNAs), large intergenic non-coding RNAs (lincRNAs), promoter-associated small RNAs
(PARs), repeat-associated short interfering RNAs (rasiRNAs) and enhancer RNAs (eRNAs)
[8,9]. Recent findings suggest that some structural ncRNAs (e.g. snoRNAs) not only have
infrastructural function but have regulatory as well [8].
Based on length, the regulatory ncRNAs can be divided in two groups: larger than 200
nucleotides (nt) are lncRNA, lincRNA, eRNA, whereas the others are smaller than 200 nt, with
exception of PARs that are 16-30 nt long or up to 200 nt. Distinct classes of small RNAs are
distinguished by their origins, and these are: snRNAs, snoRNAs, miRNAs, piRNAs, siRNAs,
and rasiRNAs [8,9].
miRNAs and snoRNAs share similarities in processing pathways and protein interaction
partners, genomic organization and location, as well as levels of conservation. However,
similarities in sub-cellular localization have been also observed, since large proportion of
human mature miRNAs have been detected in the nucleus as well as a subset of small RNAs
derived from snoRNAs have been detected in the cytoplasm [10].
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Functional role
The most widely studied and characterized of all the regulatory ncRNAs are miRNAs. The
roles of regulatory ncRNAs, other than miRNAs, in the mediating transcriptional regulation,
chromatin remodelling, post-transcriptional regulation, and other processes are less well
understood. The contexts of gene regulation by ncRNAs in non-human systems provided
insights into how these processes could function in human cells. Regulatory ncRNAs are
involved in diverse cellular pathways, such as development and stem cell maintenance,
response to stress and environmental stimuli, regulating chromatin structure and remodelling,
chromosome architecture and genome integrity, transcription (positive or negative impact),
and post-transcription processing (splicing, transport) and most commonly mRNA stability
(translation, degradation) [8,9]. Some ncRNAs trigger different types of gene silencing that are
collectively referred to as RNA silencing or RNA interference [11].
RNA interference (RNAi)
RNAi is RNA-guided regulation of gene expression, historically known by other names,
including post-transcriptional gene silencing. It is believed to be an evolutionary conserved
mechanism in response to presence of foreign dsRNA in the cell. A key step in this silencing
pathway is the processing of dsRNAs into short RNA duplexes of characteristic size and
structure. The enzyme Dicer, which initiates the RNAi pathway, cleaves dsRNA to short
double-stranded fragments of 20–25 base pairs (bp), named siRNAs. siRNAs usually possess
perfect complementarity to the mRNA of target gene, thus causing its degradation. When the
dsRNA is exogenous, coming from infection by a virus with RNA genome or laboratory
manipulations, the RNA is imported directly into the cytoplasm where it is cleave by the Dicer.
On other hand, the initiating dsRNA could be result of endogenously expressed RNA-coding
genes from the genome. Some of small regulatory RNAs are processed in a similar way or with
components of RNAi pathway [11].
2.1. Brief introduction to miRNAs
Genomic organization
miRNAs are endogenously expressed small (~22 nt), single-stranded ncRNAs. It is predicted
that they constitute ~1-5 % of human genes [1,12] and in an update from August 2012, miRBase
v19 was released with a list of 2019 unique mature human miRNAs. miRNAs are encoded as
a single gene or gene clusters, with some of miRNA clusters being co-regulated and co-
transcribed. Intergenic miRNAs are transcribed as an independent transcription unit, as a
monocistronic, bicistronic or polycistronic primary transcripts [13]. Up to 60 % of currently
known miRNAs are proposed to be from intronic sequences of either protein coding or non-
coding transcription units and suggestion has been made that some miRNAs are also encoded
in antisense DNA, which is not transcribed to the mRNA. Intronic miRNA are preferentially
transcribed in the same orientation as the host gene and are together with their host transcripts
co-regulated and co-transcribed from the same promoter. They are processed from introns, as
are many snoRNA. Within the genome, there might be more than one copy of particular
miRNA [13,14].
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Biogenesis
miRNAs expression is determined by intrinsic cellular factors and diverse environmental
variables  [1].  As  for  protein-coding  genes  it  is  known,  that  regulation  of  miRNA  tran‐
scription  and  expression  depends  on  transcription  factors  and  epigenetic  mechanisms
(e.g. p53, Myc, and myogenin). In general, from genes encoding miRNAs is transcription
guided by RNA-polymerase II (Pol II). Resulting primary transcript (several hundred bas‐
es  to  several  kilobases),  named  pri-miRNA,  forms  distinctive  hairpin-shaped  stem-loop
secondary  structure  and  contains  poly-A  tail  and  a  cap,  similarly  to  protein-coding
mRNA. pri-miRNA  is processed in the nucleus by Drosha, an RNase III enzyme. The re‐
sulting 70-nt stem-loop structure called pre-miRNA  with a 5' phosphate and 3' 2-nt over‐
hang  is  imported  into  the  cytoplasm by  a  transporter  protein,  Exportin  5.  The  double-
stranded RNA portion of  pre-miRNA  is  bound and cleaved by Dicer,  another  RNase III
enzyme,  which produces a  miRNA:miRNA* duplex (a  transient  intermediate in miRNA
biogenesis,  20–25 nt).  One of the two strands of each fragment is together with proteins
argonaute  (Ago),  incorporated  into  a  complex  called  the  miRNA-containing  ribonucleo‐
protein complex (miRNP).  It  is  believed that the guide strand  is  determined on the basis
of the less energetically stable 5' end. The resulting complex base-pair with complementa‐
ry  3'-UTR  mRNA  sequences.  The  other  strand,  miRNA*  is  presumably  degraded,  al‐
though there are increasing evidence that either or both strands may be functional [2,9].
The schematic overview of canonical miRNA biosynthesis pathway has been represented
elsewhere [15].
Numerous  alternative  pathways  differing  from  canonical  miRNA  biogenesis  pathway
have been described recently and subset of several diverse longer non-coding RNAs can
serve as precursors for miRNAs [10,16]. As an example, intronic miRNAs presumably by‐
pass  Drosha  cleavage,  since  through  pre-mRNA  splicing/debranching  machinery  is  pro‐
duced  an  approx.  60-nt  hairpin  precursor  miRNA  (pre-miRNA)  that  enter  biogenesis
pathway at the step of Exportin 5 [14]. However, some of the post-transcriptional mecha‐
nism include miRNA editing, which is mechanism mediated by adenine deaminase of al‐
teration of  adenines to  inosines,  and not  yet  thoroughly studied regulations of  miRNA,
such as export step from nucleus or miRNAs turnover rate [17].
miRNAs mechanism
The functional role of miRNA varies, but the primary mechanism of miRNA action in
mammals is believed to be base-pairing to 3'-UTR of target mRNA followed by inhibition of
mRNA translation (when base pairing between these two molecules is incomplete) or deade‐
nylation and degradation (perfect complementarity of miRNA:mRNA binding) [9]. Especially
in animals, the primary mechanism of miRNA action is reducing mRNA translation and each
miRNA can inhibit the translation of as many as 200 target genes. In addition, mRNA can be
regulated by more than one miRNA. The cooperative action of multiple identical (multiplicity)
or different miRNPs (cooperativity) appears to provide the most efficient translational
inhibition. Additional mechanism to increase the specificity of miRNAs is combinatorial
control of gene expression, which may be also provided by a set of co-ordinately expressed
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miRNAs. Proteins or mRNA secondary structures could restrict miRNP accessibility to the
UTRs, or may facilitate recognition of the authentic mRNA targets [12,13,18,19].
There is the prospect that some miRNA might specify more than just post-transcriptional
repression [9,13]. miRNAs may also target promoter to regulate transcription through
epigenetic mechanism. miRNAs have been paradoxically also shown to up-regulate gene
expression by enhancing translation under specific conditions [9].
Biological function
Translational repression, as major mechanism of miRNAs, may in normal cell conditions occur
in different ways: as switch off the targets, that is for mRNAs that should not be expressed in
a particular cell type, the protein production is reduced to inconsequential levels; as fine-tuners
of target expression, that is when miRNAs can adjust protein output for customized expression
in different cell types; as neutralizers of target expression, that is when miRNAs act as
bystanders, where down-regulation by miRNAs is tolerated or reversed by feedback processes
[13]. Role of miRNA can be further divided in three paradigms: combinatorial control (defined
as cooperativity), cell-to-cell variation, specific (tissue-specific and/or cell-type specific) and
housekeeping functions [20].
Despite the large number of identified miRNAs, the scope of their roles in regulating cellular
gene expression is not fully understood [11]. It is believed that miRNAs through negative gene
regulation influence at least 50 % of genes within the human genome [9]. Expression profiling
of many miRNAs in various normal and diseased tissues have demonstrated unique spatial
and temporal expression patterns. Many miRNAs are important at distinct stages of develop‐
ment and have been found to regulate a variety of physiological and pathological processes
[11]. miRNAs are involved in a numerous biological processes, such as stem cell division and
developmental timing, proper organ formation, embryonic pattering and body growth,
proliferation and differentiation, apoptosis, epithelial-mesenchymal-transition (EMT),
cholesterol metabolism and regulation of insulin secretion, resistance to viral infection and
oxidative stress, immune response etc. [2,11]. All these effects may occur by regulating or being
regulated by the expression of signalling molecules, such as cytokines, growth factors,
transcription factors, pro-apoptotic and anti-apoptotic genes [21]. With all different genes and
expression patterns, it is reasonable to propose that every cell type at each developmental stage
might have a distinct miRNA expression profile.
Defining miRNA targets and databases
Up  to  date,  over  2000  human  miRNAs  have  been  identified  and  this  number  is  still
growing. All  annotated miRNAs are collected in miRBase [22].  The first  step in miRNA
target identification is usually defining reciprocally regulated miRNA-mRNA or miRNA-
protein. Since miRNAs target mRNA mainly by incomplete base-pairing, many computa‐
tional  methods  have  been  recently  developed  for  further  identifying  potential  miRNA
targets [23].  Most of  these methods search for three criteria in predicting miRNA target
genes:  first,  multiple  conserved  regions  of  miRNA  complementarities  within  3'-UTR  of
target mRNA (evolutionary conservation); second, interaction between seven consecutive
nucleotides in the target mRNAs 3'-UTR and the 1-8 nt (“seed sequence”) at the 5' miR‐
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NA end; third, stability of base pairing and predicted binding energy. Further complicat‐
ing  target  site  prediction  in  mammals  is  the  fact  that  not  all  3'-UTR sites  with  perfect
complementarities to the miRNA seed nucleotides are functional. Moreover, mRNAs sites
with  imperfect  seed  complementarities  can  themselves  be  very  good  miRNA  targets
[24,25].  Bioinformatics  is  therefore  much  noisier  and  more  prone  to  false  positive  and
false negative predictions. Among many available programs for predicting mRNA targets
for specific miRNA, none of these programs can be used as an independently approach
for  validating the targets,  and all  predicted targets  must  be  validated in  vitro  and/or  in
vivo.  Thus the gold standard for miRNA target identification is the experimental demon‐
stration that a luciferase reporter fused to the 3'-UTR of the predicted target is repressed
by over-expression of  the  miRNA and that  this  repression is  abrogated by point  muta‐
tion in the target sequences in 3'-UTR [26,27]. Finaly, expression profiling in human dis‐
ease  gives  the  starting point  for  target  verification/validation and association to  disease
prognosis and pathogenesis.  All  identified disease related miRNAs are listed in The hu‐
man microRNA disease database (HMDD), where you can search for specific miRNA, for
tissue expression of annotated miRNAs, and for disease related miRNAs [28].
2.2. Brief introduction to lncRNA
Genomic organization
LncRNAs are those longer than 200 nt,  and many of them can also act as primary tran‐
scripts for the production of short RNAs [9]. It is estimated that total number of lncRNA
transcripts,  including  new  unexplored,  is  approx.  15000.  Thousands  of  protein-coding
genes  in  humans  harbour  natural  antisense  transcripts  (approx.  61  % of  transcribed re‐
gions  show  antisense  transcription)  belonging  to  the  lncRNA,  and  majority  of  known
lncRNAs in some way overlap protein-coding loci.  All  these data are giving the impor‐
tance to lncRNA annotation [29].
Classification
LncRNAs can  be  classified  according  to  their  proximity  to  protein  coding genes.  There
are five categories of lncRNAs: sense, antisense, bidirectional, intronic, intergenic. Just to
mention  a  few  of  them,  lincRNAs,  a  class  of  ncRNAs,  exhibit  a  high  conservation  be‐
tween different species;  they both up- and down- regulate hundreds of gene expression
and  participate  in  the  establishment  of  cell  type-specific  epigenetic  states  [9].  Further,
ncRNAs were found expressed at enhancer regions, suggesting that some enhancer RNA
is  also  transcribed with  an average  size  of  800  nt;  these  transcripts  are  termed eRNAs.
Studies  propose  a  possible  role  for  eRNAs as  transcriptional  activators,  however,  ques‐
tion remains whether such eRNAs are in fact a subset of the activating lncRNAs. Similar
to  eRNA,  a  novel  diverse  class  of  ncRNAs  has  been  linked  to  the  promoters,  called
PARs,  ranging from 16-36 nt  to 200 nt.  It  is  suggested that  they participate in the tran‐
scriptional regulation [9].  Most lncRNAs are characterized by low expression levels,  low
level of sequence conservation, by composition of poly-A tail and without poly-A tail as
well  as by spliced and un-spliced forms. They are believed to have nuclear localization,
but can also accumulate in cytoplasm of cells [3].
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Function
lncRNAs may act through diverse molecular mechanisms, and play regulatory as well as struc‐
tural roles in different biological processes [3]. Many of the identified lncRNAs show spatial-
and temporal-specific patterns of expression. Almost every step in the life cycle of genes –
transcription, mRNAs splicing, RNA decay, and translation – can be influenced by lncRNAs.
Generally lncRNAs have been implicated in gene-regulatory roles, such as chromatin dosage-
compensation, imprinting, epigenetic regulation, cell cycle control, nuclear and cytoplasmic
trafficking, cell differentiation etc. [7]. A number of studies suggest that lncRNAs are key com‐
ponents of the epigenetic regulatory network [4]. Two general modes of lncRNAs regulation
seem to be important: interaction with chromatin remodelling complexes that promote silenc‐
ing of specific genes; and modulation of splicing factors. Chromatin remodelling guided by
ncRNAs contributes to the establishment of chromatin structure and to the maintenance of epi‐
genetic memory. Various ncRNAs have been identified as regulators of chromatin structure
and gene expression [30]. Additional mechanisms of action are yet to be revealed [3].
Database
The lncRNA database provides sequence, structural, and conservation evidence for multi-
species lncRNAs, together with a list of lncRNAs that are experimentally known to interact
with coding mRNAs, harbouring other short ncRNAs and other characteristics of specific
lncRNA [29].
3. Involvement of ncRNA in cancer
Three major mechanisms are known to give rise to deregulated ncRNAs function, genetic
alterations, epigenetic alterations, and in case of miRNAs, an aberrant miRNA biogenesis
machinery. Since brief overview of first two mechanisms is described below, will be here
mentioned only aberrant machinery of miRNA processing. Proteins involved in miRNA
biogenesis (Drosha, Dicer, Ago) are deregulated in several cancers. Co-factors involved in
miRNA biogenesis can be mutated causing consequently deregulation of Dicer; Exportin 5,
mediating pre-miRNA nuclear export, is often mutated and truncated, leaving pre-miRNAs
within nucleus [31,32].
3.1. Mutations, SNPs and epigenetics of ncRNAs
Cancer cells have different genetic and epigenetic changes from their normal counterparts and
the role of ncRNAs in mediating these differences is beginning to emerge. Specific genetic
polymorphisms are associated with the risk of developing several types of cancer [7-9].
Multiple studies have identified small-scale and large-scale mutations and genomic alterations
affecting also noncoding regions of the genome. Some of these mutations are structural
alterations, rearrangements and chromosomal translocation, amplification, loss of heterozi‐
gocity and copy-number variation, nucleotide expansion, and single-nucleotide polymor‐
phisms (SNPs), and they are linking distinct types of mutations in ncRNA genes with diverse
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diseases [7]. First, lncRNA have already been implicated in human diseases such as cancer and
neurodegeneration [33]. Second, approx. half of miRNA genes are encoded in genomic region
prone to cancer-associated rearrangements or in fragile chromosomal sites (amplified, deleted
or rearranged) that are often associated with cancer, such as ovarian and breast carcinomas,
and melanomas [8,11]. Third, presence of SNPs in miRNAs, where disruption of miRNA target
interaction either in the miRNA gene or its target site (3′-UTR mRNA) can lead to complete
gain or loss of the miRNA function or target gene thus causing disease [34,35]. In contrast to
the miRNA target sites in mRNA transcripts, where the potential of variation is huge, variants
identified in miRNA precursor sequences tend to be rarer [36]. The presence of SNPs in pri-
miRNA or pre-miRNA can in addition affect the processing of miRNAs, their expression
and/or binding to target mRNA [27,37]. Forth, recent advances in miRNA research have
provided evidence of a miRNA association with epigenetic mechanisms activated in diseased
human tissues [38]. Heritable changes in gene expression that do not involve coding sequence
modification are referred as epigenetics. Gene regulation by ncRNAs was considered as an
epigenetic mechanism, but ncRNAs can be regulated by the same mechanism in which they
participate [39]. DNA methylation, one of the two major epigenetic mechanisms, leads to gene
silencing, and serves as an alternative mechanism of gene inactivation. The aberrant DNA
methylation of gene promoters has been shown to result in the inactivation of tumour
suppressor genes [40]. For an example, miR-34 family is a family of tumour suppressors’ genes,
with miR-34a being deregulated by DNA methylation in both epithelial and haematological
cancers. miR-34 is an important component of the p53 tumour suppressor network, and p53 is
a predicted target for members of the miR-34 family. miR-34a reinforces the tumour suppressor
function of p53, transactivation of miR-34a by p53 was also shown to promote apoptosis
[11,41-44]. Another example is that miR-29s could target two enzymes of methylation process,
DNMT3A and DNMT3B [39]. Antisense ncRNAs have been recently showed to be implicated
in the silencing of tumour suppressor genes through epigenetic remodelling events [30]. All
these miRNAs abnormalities suggest that they play a broad role in cancer pathogenesis.
3.2. Promising role of ncRNAs in cancer: As cancer-subtype classifiers and detection in body
fluids
ncRNAs have been recognized as gene-specific regulators. They are similar in activity to a
large number of protein transcription factors that are known to be critical in the transformation
of cells to a malignant state. Majority of research has been involved in defining the role of
miRNAs in cancer; however, lincRNAs have been shown to play role in tumour development
by promoting the expression of genes involved in metastasis and angiogenesis [9]. Genome-
wide analyses have shown that ncRNAs have distinct signatures specific for a certain cancer
type. Importance of combining ncRNAs with other biomarkers for cancer detection and
prognosis would improve cancer risk assessment, detection, and prognosis. Thus, there is a
need to combine genomic mutations with ncRNA markers to develop marker panels for more
accurate risk assessment and early diagnosis [7-9].
Most cancers are diagnosed in advance stages, leading to poor outcome. Intense investiga‐
tion is going on seeking specific molecular changes that are able to identify patients with
early cancer or precursor lesions [1]. Genome-wide expression profiling has examined miR‐
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NAs in preneoplasia or their usefulness to predict progression from preneoplasia to cancer.
Several lines of evidence suggest the potential usefulness of ncRNAs, particularly miRNAs:
first, as signature of early events in carcinogenesis and as biomarkers in early cancer detec‐
tion, second, as differential indicators of benign tumours, preneoplasia, and neoplasia, and
third, that miRNAs and perhaps other ncRNAs might be useful in determining which pre‐
neoplastic lesions are likely to progress to cancer. Distinguishing benign diseases and cer‐
tain non-precancerous lesions from precancerous lesions and metastatic tumours would
improve patient outcomes, survival, and reduce patient discomfort [45]. Characterization of
ncRNAs involved in the development or maintenance of oncogenic states may therefore de‐
fine ncRNAs as early biomarkers for the emergence of cancer, and could have have an im‐
pact on the development of tools for disease diagnosis and treatment [30].
miRNAs are believed to be promising potential biomarkers for cancer diagnosis, prognosis
and targets for therapy. As potential markers for diagnosis are better classification factors
than mRNAs. miRNAs seems to be evolutionarily selected gene regulatory molecules, their
expression profiles might therefore be rich in gene regulatory information. Only small per‐
centage of the 16000 genes on the mRNA-expression arrays are regulatory molecules. This
difference may be responsible for more efficient microRNA expression arrays in classifying
cancer than mRNA-expression arrays [21,45,46]. Some of the key features of miRNAs that
make them useful as potential biomarkers can be briefly summarized. First, expression pat‐
terns of miRNAs in human cancers appear to be tissue specific. Second, miRNA profiles ap‐
pear to reflect developmental lineage and differentiation state of the tumours. Third,
miRNAs can successfully classify poorly differentiated tumours with high accuracy (~70 %).
In contrast, mRNA profiles in the same set of specimens had an accuracy of only 6 %. There‐
fore, a combination of both miRNA and mRNA profiling data has the potential of enhancing
accuracy of tumour classification. Forth, miRNAs can also be profiled and quantitatively
measured in formalin-fixed paraffin-embedded tissues. And last, miRNAs are stable in hu‐
man body fluids of plasma and serum and can be quantitatively measured in microliter
quantities of human sera or plasma using qPCR. [45-47].
Highly stable cell-free circulating nucleic acid (cfCNA), both RNA and DNA, has been dis‐
covered in the blood, plasma, and urine in humans. Since there is good correlation between
tumours and genetic, epigenetic and/or transcriptomic changes and alterations in cfCNA
levels, it gives a usefulness of cfCNA as biomarkers for clinical applications. Release of
cfCNA in body fluids is probably related to apoptosis and necrosis. Circulating RNAs are
stable in serum and plasma in spite of high amounts of RNAase in blood of cancer patients
[48]. They are packed in microparticles, of which the most analyzed are in recent years exo‐
somes [3,49,50]. Tumour derived exosomes are small membrane vesicles of endocytic origin
released by the tumour and found in peripheral circulation. Several recent reports showed
that exosomes could be an important resource of cf-lncRNA/cf-miRNA in serum or plasma
[51]. Small size, relative stability and resistance to RNAase degradation make the miRNAs
more superior molecular markers than mRNAs [1]. Using non-invasive diagnostic proce‐
dures, the extraction and reliable determination of cf-miRNAs, circulating in body fluids
like plasma, serum, and others, could serve as circulating tumour biomarkers [52,53].
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LncRNAs show greater tissue specificity compared to protein-coding mRNAs, making them
attractive in the search of novel diagnostics and/or prognostics cancer biomarkers in body fluid
samples. For an example, lncRNA PCA3 was initially identified as over-expressed in prostate
tumours relative to benign prostate hyperplasia and normal epithelium. It was latter showed
that is very specific prostate cancer gene, whose mechanism is not yet identified, but it can be
detected in urine samples and has been shown to improve diagnosis of prostate cancer [3].
3.3. ncRNAs can act as both tumour suppressor genes and oncogenes
There are different ways in which miRNAs appear to be involved in cancer:  as tumour
suppressors,  as oncogenes,  or as agents involved in affecting genome stability.  Below is
discussed role of miRNAs acting both, as tumours suppressor and as oncogenes, since are
much more investigated in this field than are lncRNAs. Care must be taken in assigning
oncogenic or tumour suppressor activity to a miRNA, since miRNA expression patterns
are highly specific for cell-type and cellular differentiation status.  The same miRNA can
function as  tumour suppressor  in  one cell  type and as  potential  oncogene in  other  cell
type. Some of the aberrant miRNA expression observed in tumours may also be a secon‐
dary  consequence  of  the  loss  of  normal  cellular  function  that  accompanies  malignant
transformation. Up- or down-regulation of a miRNA in a given tumour type is not obvi‐
ous a causative role in tumorigenesis [6].
The increased expression of oncogenic miRNAs appears to act in a manner analogous to an
oncogene. Over-expression of oncogenic miRNAs are presumed to function by down-
regulating the levels of protein product of target tumour suppressor gene or by reduction of
tumour suppressor processes, such as apoptosis [2,6,20]. A loss of expression of tumour
suppressor miRNA may lead to elevated levels of the protein products of target oncogenes [6],
activation of an oncogenic processes, such as proliferation [2,20]. MicroRNAs with anti-
proliferative and pro-apoptotic activity are likely to function as tumour suppressors and thus
may be under-expressed in cancer cells. Figure 1 represents schematic overview of miRNAs
acting as tumour suppressors or oncogenes in comparison to non-cancerous cells.
There should be at least four type of evidence before assigning tumour suppressor function to
ncRNAs: (i) data about widespread deregulation in diverse cancer, (ii) gain or loss of function
in tumours owing to deletion, amplification or mutation, (iii) direct documentation of tumour
suppressing activity using cell line or animal models, (iv) the identification and verification of
cancer relevant targets that define mechanisms through which miRNAs participate in onco‐
genesis [6].
4. ncRNAs as potential therapeutic targets in cancer
4.1. RNAi in therapeutic applications
Using RNAi approaches, ncRNAs may in future serve as therapeutic targets. For ncRNA that
is under-expressed and possess tumour suppressor function, re-introduction of the mature
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Figure 1. Schematic overview of miRNAs acting as tumour suppressors or oncogenes.
MicroRNAs and lncRNAs as Tumour Suppressors
http://dx.doi.org/10.5772/54701
55
ncRNA into the affected tissue would restore the regulation of the target gene. By contrast,
over-expressed ncRNA with oncogenic function could be down-regulated by reducing mature
ncRNA level by its direct targeting [54].
Due to the interferon response it is difficult to introduce long dsRNAs into mammalian cells,
however, the use of RNAi as a therapeutic approach has been successfully used. Among the
first applications to reach clinical trials were in the treatment of macular degeneration and
respiratory syncytical virus infection, reversal of induced liver failure in mouse models,
antiviral therapies, neurodegenerative diseases, and cancer. Cancer was treated by silencing
up-regulated genes in tumour cells or genes involved in cell division. A key area of research
in the use of RNAi for clinical applications is the development of a safe delivery method, which
to date has involved mainly viral (lentivirus, adenovirus, adeno-associated virus) and non-
viral (nanoparticles, aptamers, stable nucleic-acid-lipid particle, e.g.) vector systems similar to
those suggested for gene therapy [55].
4.2. ncRNAs with tumour suppressor function as therapeutic targets
Replenishing small RNAs/miRNAs
Pharmacological manipulation of miRNAs is still  in its infancy; however, the correlation
between the expression of miRNAs and their effects on target oncogenes, on tumorigene‐
sis, and on the proliferation of cancer cells has gained experimental support. miRNAs are
small  molecules,  making their  in vivo  delivery feasible.  It  has been shown that miRNAs
can  be  delivered  systematically,  and  can  reduce  invasion,  proliferation  and  growth  as
well as induce radio-sensitivity and resistance. miRNAs may therefore serve as therapeu‐
tic targets in the future.
For miRNA that is under-expressed, re-introduction of the mature miRNA into the affected
tissue would restore regulation of the target gene. For this purpose, artificial miRNA (miRNA-
mimic) have been developed to enhance the expression of beneficial miRNAs or the introduc‐
tion of short hairpin duplex, similar to pre-miRNA, into the cell. This suggests that individual
miRNAs are potential therapeutic agents, provided that their expression or delivery can be
targeted to appropriate tissue. Most of the developed protocols have used local administration
in easily accessible tissue; systemic delivery has also give some promising results; the major
challenge remains tissue and cell-type specific targeting [56].
miRNA mimic can only last a couple of days and the long term biological effects were not
observed very effectively. To overcome this, the cells were infected with a lentivirus that
expressed mature miRNAs. This generated stable cell expressing miRNAs. miRNA mimics
and lentiviral miRNAs showed great potential in restoring tumour suppressor miRNAs.
However, viral and non-viral delivery systems have been developed. Viral vector-directed
methods show high gene transfer efficiency, but have some limitations. However, non-viral
gene transfer vectors have been also developed: cationic liposome mediated gene transfer
system, lipoplexes, neutral lipid emulsion, etc. [57].
Expression  of  miRNA-mimic  would  simultaneously  suppress  many  gene  targets.  miR‐
NAs-mimic would be useful in conjunction with standard chemotherapy or radiotherapy,
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by influencing drug resistance or enhancing responsiveness to therapy. Current limitation
is need for improvement of efficiency of delivery to target tissue,  for systemic drug ad‐
ministration,  potential  inhibition  of  non-target  genes  (“off-target  effect”),  redundancy
among miRNAs efficacy, potential toxicity and immunogeneic responses. However, stud‐
ies  introducing  miRNAs  strategies  to  inhibit  cancer  propagation  in  animal  models  are
showing promising results [32].
Examples for miRNA
Therapeutic delivery to animal models was demonstrated using miRNA-mimics of the tumour
suppressor miRNAs, miR-34a and let-7a, both of which are often down-regulated or lost in lung
cancer. It has been shown that re-introduction of let-7 directly represses cancer growth in the
lung [58] and that development of chemically synthesized therapeutic miR-34a and lipid-based
delivery vehicle block tumour growth in mouse models of non-small-cell lung cancer (NSCLC)
[59]. Systemic treatment of these mice led to significant decrease in tumour burden. Mice
treated with miR-34a displayed a 60 % reduction in tumour area compared to mice treated with
a miRNA control. Similar results were obtained with the let-7 mimic [60].
Targeting lncRNAs
Successful inhibition of lncRNAs seems to be more difficult than inhibition of miRNAs. Our
growing knowledge of other ncRNAs might exploit in future to develop new therapeutic
strategies not only against cancer, but also for other diseased states. The findings regarding
lncRNA and Alzheimer disease are attracting the attention of pharmaceutical and biotechnol‐
ogy industries [8]. Therapy using small RNAs that targets ncRNA transcripts, such as eRNAs
or PARs, may represent a new way to treat disease conditions caused by epigenetic changes [9].
Targeting both, lncRNAs and miRNAs
Another possible approach for manipulation of ncRNAs level may also be by altering DNA
methylation. As mentioned above, DNA methylation is a crucial mechanism associated with
epigenetic regulation. It has been shown that in cancer cells treated with DNA demethylating
agent reactivation of certain miRNAs occurs [40]. ncRNAs mediated therapy may also be
useful in combination with DNA methyltransferase inhibitors that are other way toxic [39].
5. ncRNAs as tumour suppressor in different types of cancers
5.1. miRNAs as tumour suppressors
In the following section, down-regulated miRNAs will be describe and miRNAs with sug‐
gested tumours suppressive roles in different types of cancer. However, down-regulation does
not ncessary mean that miRNA is tumours uppressor.
Hematological cancers
Leukaemia. Chronic lymphocytic leukaemia (CLL) is characterized by overexpression of the
protein Bcl-2 in B cells and represents the most common human leukaemia. In less than 5 %
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of cases, over-expression of Bcl-2 is due to a translocation of the Bcl-2 gene, whereas for the
majority of CLL cases no explanation for the deregulation of Bcl-2 has been reported. It has
been demonstrated that mutations in genomic regions containing miRNAs were associated
with disease progression in a number of CLL patients. In this type of cancer, miR-15 and miR-16
expression is often reduced and indeed, one of the first associations between miRNAs and
cancer development was observed for miR-15 and miR-16 in CLL [46]. Both miRNAs are located
in a 30 kb region on chromosome 13 that had been found deleted in more than half of B cell
CLL (chromosome 13q14 deletion) [8,46], and miR-15a and miR-16-1 have been shown to be
deleted or translocated in approx. 65 % of CLL patients [2,11]. Several papers indicate that
miRNA regulates cell growth and apoptosis. Indeed, over-expression of miR-15 and miR-16
directly inhibit anti-apoptotic Bcl-2, a key player in many types of human cancers, and thus
activate apoptotic processes [2,11]. However, it was further demonstrated that other mutations
in miRNA genes are frequent in CLL; many mutations were located in the flanking sequence
of pre-miRNA, thus cell culture assay indicated that a point mutation of the miR-16-1 precursor
abolishes expression of mature miR-16 [21]. Few other miRNAs were also recognized as
tumour suppressors in CLL. miR-29a and miR-29b are associated with fragile site FRA7H that
is not associated with any known tumour suppressor gene. Over-expression of miR-29b may
target TCL1 and reduces anti-apoptotic Mcl-1 protein in CLL patients [11]. Another well-
known tumour suppressor was analysed. Low expression of miR-34a in CLL was found to be
associated with p53 inactivation, impaired DNA damage response, apoptosis resistance and
chemotherapy-refractory disease irrespective to p53 mutation (cases with CLL with p53
mutation are resistant to chemotherapy). It was latter showed that miR-34a is induced by p53.
In another type of leukaemia, particularly acute myeloid leukaemia, an inverse correlation
between miR-34b and CREB expression has been observed. After restoring expression of
miR-34b, cell cycle abnormalities, reduces growth and altered CREB expression has been
observed, suggesting tumour suppressor potential of this miRNA [47].
Lymphoma.miR-142 gene was found at the junction of the t(8;17) translocation, which may
contribute to the progression of an indolent lymphoma into aggressive B-cell leukaemia [21].
Breast cancer
Breast cancer is one of the most important cancers in adult females. miR-125b, miR-145, miR-21
and miR-155 were significantly reduced in breast cancer tissue and this expression was
correlated with specific breast cancer pathologic features, such as tumour stage, proliferation,
oestrogen and progesterone receptor expression, and vascular invasion. Some of these
miRNAs act as oncogenes (e.g. miR-21) in many cancer types, so it is suggested that some
miRNAs act as tumour suppressors in one cancer type and as oncogenes in another [2].
miR-125b-1 is located on a fragile site on chromosome 11q24, which is deleted in a subset of
patients with breast cancer [61]. Down-regulation of mir-221 in breast cancers was detected,
whereas germ line mutation in mature miR-125a is highly associated with breast cancer
tumorigenesis, suggesting its tumour suppressor role. miR-125a is also down-regulated in
human breast cancer and when over-expressed post-trancriptionally regulates CYP24 result‐
ing in an anti-proliferative effect. Ectopic expression of miR-30e suppresses cell growth in
breast cancer, probably through targeting Ubc9 [47]. miR-17-5p was down-regulated in breast
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cancer cells, and enhanced expression decreased tumour cell proliferation [11]. Cyclin D1 has
been identified as a direct target for miR-17/20 that functions to suppress proliferation of breast
cancer cells. Additional miRNAs have also been shown to be down-regulated and have tumour
suppressor function in other types of cancer: let-7, miR-145, miR-34a, miR-214, and miR-205.
MicroRNAs, miR-31, miR-126, miR-146a/b, miR-206 and miR-335 have been shown as anti-
metastatic miRNAs [62,63].
Colorectal Cancer (CRC)
Colorectal cancer is the third most commonly diagnosed cancer in the world, but it is more
common in developed countries. Also in colorectal neoplasia miRNAs expression is associated
to the tumour formation. Reduced expression of miR-143 and miR-145 have been shown to be
a frequent feature of colorectal tumours (adenomatous and cancer stage) when compared to
normal mucosa [2,6,64]. A tumour suppressive role of miR-143 has been elucidated in the
epigenetic aberration of CRC with DNMT3A as a target. Restoration of miR-143 expression in
CRC decreases tumour cell growth and down-regulates DNMT3A expression [47]. let-7 has
been implicated in development of colon cancers and progression of colorectal cancers;
together with miR-143 and miR-18a was observed to be down-regulated and target KRAS [11,
64]. miR-145 has been proposed as a tumour suppressor and it has been shown that target
IRS-1, and when over-expressed it dramatically inhibits the growth of colon cancer cells. A
ubiquitous loss of miR-126 expression in colon cancer lines was observed and its reconstitution
resulted in a significant growth reduction. Also, in a panel of matched normal colon and
primary colon tumours, each of the tumours demonstrated miR-126 down-regulation [64].
Down-regulation of miR-200 family is a hallmark of EMT as well as up-regulation of ZEB1
transcription factor, and it was shown that in colorectal cells ZEB1 directly suppress tran‐
scription of miR-141 and miR-200c [57]. It was found that miR-192 and miR-215 was down-
regulated in CRC, and their anti-proliferative effect was identified in CRC cell lines. It was
further defined that both are regulated by p53 and that their targets are a number of transcripts
that regulate cell cycle checkpoints [57]. An inverse correlation between COX-2 and miR-101
was reported in CRC cell lines, and this was further confirmed in colon cancer tissue and liver
metastases derived from CRC patients. miR-16, miR-125b, miR-31, miR-133b, and miR-96 were
along with already mentioned miRNAs showed to be down-regulated in colorectal cancer [1].
Aberrant DNA methylation may further induce silencing of specific miRNAs in CRC. While
methylation of miR-129 and miR-137 CpG islands is frequently observed in CRC, is methylation
of miR-9-1 associated with the presence of lymph node metastasis and expression of miR-9 in
CRC inversely correlated with the methylation of its promoter regions [47]. In human colon
cancer cell lines, miR-34a was showed to participate in the apoptotic program triggered by p53
activation and loss of miR-34a expression occurs frequently in cancer cells. p53 directly binds
to the genomic region defined as the miR-34a promoter with consequent miR-34a targeting
genes of cell cycle, DNA repair, mitotic checkpoint, DNA integrity checkpoint, cell prolifera‐
tion, and angiogenesis. Among the down-regulated targets of miR-34 family were well-
characterized p53 targets, such as CDK4/6, cyclin E2, E2F5, BIRC3 and Bcl-2. These effects were
nearly identical irrespective of whether miR-34a, miR-34b or miR-34c was introduced into cell
lines. Another target was identified for miR-34a, SIRT1, negative regulator of apoptosis.
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miR-34a promoter hyper-methylation was observed in 3 of 23 cases of colon cancer, miR-34b/c
were found to be epigenetically silenced in 9 of 9 cell lines and in 101 of 111 primary CRC
tumours [42,64].
Gastric cancer
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death
in the world. It was reported that loss of Ago2, which leads to premature stopping of miRNAs
biogenesis and general deregulation of miRNAs expression, was observed in 40 % of human
gastric cancer patients with high microsatellite instability. A number of miRNAs were reported
to be down-regulated. Among these, miR-141 was significantly low expressed in 80 % of
primary gastric carcinoma compared to non-cancer adjacent tissue. It targets FGFR2 and its
down-regulation means proliferative potential and poor differentiation of gastric cancer cells
[65]. It appears that down-regulation of miR-451 is related to the worse prognosis of the gastric
cancer patients. Over-expression of miR-451 in gastric cancer cells regulates the oncogene MIF
production, reduces cell proliferation and increases sensitivity to radiotherapy [47]. miR-101
was down-regulated in gastric cancer cells, its targets are: EZH2, Cox-2, Mcl-1, and Fos [65].
Other potential tumour suppressor miRNAs in gastric cancer are: miR-181b/c and miR-432AS,
and for miR-181 it was proposed that modulate expression of Bcl-2. Low level or loss of
expression in gastric cancer also showed let-7a, miR-486, and miR-449. However, a proposed
role for miR-107 and miR-126 is controversial in gastric cancer, either tumour-suppressive or
oncogenic [66].
An epigenetic silencing of miR-512-5p was observed in gastric cancer cells. As its target is was
shown anti-apoptotic protein Mcl-1 and after epigenetic treatment (demethylation), it results
in apoptosis of gastric cancer cells [65].
The association between genetic  polymorphism of  miR-196a-2  and risk  of  gastric  cancer
has  been  identified;  it  was  found that  the  variant  homozygous  genotype  of  miR-196a-2
was associated with significantly increased risk of gastric cancer [65].
Pancreatic cancer
Pancreatic cancer is the eighth most common cause of cancer-related deaths worldwide and it
has a poor prognosis for all stages. It is usually diagnosed at advent stages, therefore it is an
urgent need to find some specific biomarkers and key components of carcinogenesis. Several
miRNAs were reported to suppress metastasis. In pancreatic cancer cell lines, miR-146a was
decreased compared to normal ductal epithelial cell line, and its ectopic expression inhibited
invasive capacity of pancreatic cancer cell lines. miR-96 is believed to be a potential tumour
suppressor through targeting KRAS. It is significantly down-regulated in pancreatic cancer,
its ectopic expression induces apoptosis, inhibits cell proliferation, migration and invasion. In
human clinical samples there is observed inverse correlation between miR-96 and KRAS.
Further, ectopic expression of miR-520h has inhibitory effect on pancreatic cancer cell migration
and invasion, miR-20a, with metastasis-suppressing effect, is reduced in pancreatic cancer and
its cell lines. [67]. In pancreatic ductal carcinoma, miR-345, miR-139, and miR-142-p were the
most down-regulated miRNAs in tumour tissue compared to normal tissue [1]. Other potential
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tumour suppressor miRNAs involved in pancreatic cancer are: miR-100, miR-181a, and
miR-15b, but are as well as miR-200 family up-regulated [67].
miR-200 family, potential tumour suppressors, is up-regulated in pancreatic cancer. Low
expression of miR-200 family genes and higher expression of their target is common in different
cancers. However, most pancreatic cancer cell investigations showed hypo-methylation of
miR-200a/b and its over-expression, in contrary its targets are hyper-methylated, suggesting
that this pathway is not involved in metastases in most pancreatic cancer [67]
Hepatocellular Carcinoma (HCC)
Primary liver cancer mainly refers to HCC, which is one of the most common malignant
tumours in liver and accounts for 85-90 % of primary liver cancers. Cyclins D2 and E2 were
validated as direct targets for miR-26a, which exhibit reduced expression in HCC [68]. In
another early study on animal models, down-regulation of number of miRNAs has been
detected, including known tumour suppressor miRNAs, such as: miR-15/16, miR-34a,
miR-150 and miR-195 [69]. miR-122, which represents 70 % of all liver miRNAs, was found to
be frequently down-regulated in HCCs. Loss of miR-122 expression in tumour cells segregates
with specific gene expression profiles linking to HCC progression. miR-122 is specifically
repressed in a subset of primary HCCs that are characterized by poor prognosis and is therefore
suggested as tumour suppressor miRNA [47,68]. As one of miR-122 targets, cyclin G1 was
identified, through its regulation miR-122 influences p53 protein stability and transcriptional
activity. Two other miR-122 targets, which promote tumorigenesis, are SRF and IGF1R. The
cellular mRNAs and protein levels of Bcl-w were also repressed by miR-122. Other pro-
apoptotic functions were assigned for let-7 through targeting Bcl-xL, for miR-101 through
targeting Mcl-1, and for miR-29 through targeting Mcl-1 and Bcl2. miR-195 was significantly
reduced in HCC tissues and cell lines, it suppress tumorigenicity through targeting cyclin D1,
CDK6, and E2F3. CDK6 was showed to be also target for miR-124, which is silenced through
CpG methylation in HCC; miR-124 in addition targets vimentin, SET, and MYND. Let-7g
inhibits the proliferation of HCC by down-regulating c-Myc. Methylation of miR-1 in HCC
results in enhanced tumour cell growth, probably through release of its oncogenic targets c-
Met, FoxP1, HDAC4. miR-223 targets Stahmin 1 and is down-regulated in HCC whereas
miR-375 inhibits the proliferation and invasion of HCC cells by targeting Hippo-signalling
effectors YAP [68,70]. Research on expression profiling in HCC and adjunct non-tumour tissue
defined that miR-199a*, miR-195, miR-199a, miR-200a, and miR-125a were also under-expressed
in HCC tissue [2]. Anti-metastatic functions were showed for miR-122 by targeting desintegrin
and metalloprotease, and let-7g by targeting type I collagen A2. c-Met is target for miR-1,
miR-34a, miR-23b and miR-199a-3p, and all of these miRNAs are down-regulated in HCC
[68,70].
Lung cancer
Lung cancer is one of the most common cancers of adults and is also leading cause of cancer-
related deaths in many economically developed countries [2]. Let-7 family is a family of
miRNAs, whose genes map to different chromosome regions that are frequently deleted in
lung cancer [71]. Significantly worse survival was observed among patients with low expres‐
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sion of let-7a-2 compared to those with opposite expression pattern, independent of disease
stage [2]. Over-expression of let-7 in lung adenocarcinoma cell lines inhibited cancer cell
growth and reduced cell cycle progression. These findings reflect that let-7 mediates tumour
suppressive function [2,45]. It has been shown that let-7 regulates the expression of several
oncogenes, RAS, MYC, HMGA2, and cell-cycle progression regulators, CDC25, CDK6, cyclin
D2. let-7 is down regulated in lung tumours and its expression anti-correlated with that of RAS
relative to the normal lung tissue [46,71]. In animal models, ectopic let-7g expression reduces
tumour burden and intranasal administration repress lung adenocarcinoma. A SNP in let-7
complementary site 6 in 3'-UTR of its target KRAS is significantly associated with increased
risk for NSCLC among moderate smokers [71]. The let-7 family was subsequently found to be
deregulated in a large number of tumour types [46].
Mutations in EGFR gene are more frequent in NSCLC patients who never smoked tobacco; a
significant down-regulation of miR-145 has been demonstrated in the cancer tissues of these
patients. Restoration of this miRNA can inhibit cancer cell growth in EGFR mutant lung AD
[47,71]. miR-128b has been also showed as direct regulator of EGFR, whereas miR-128b loss-of-
heterozigocity is frequently found in NSCLC. miR-7 is frequently down-regulated in lung
cancer, it suppress EGFR and Raf1, it attenuates activation of Akt and ERK, suggesting that is
negative regulator of EGFR pathway [71].
It was proposed that miR-140 regulates PDGF in lung cancer development, but this has not yet
been thoroughly investigated. miR-29 is down-regulated in lung cancers, its targets are Mcl-1,
DNMT3A and DNMT3B, suggesting that it is pro-apoptotic and that it has role in regulating
epigenetic DNA methylation. Further, in lung cancer cells induction of miR-34 results in
apoptosis; miRNA profiling revealed that miR-34a/b/c are directly correlated with expression
of p53. Decreased expression of miR-126 and increased expression of VEGFA was found in
various lung cancer cell lines. Introduction of miR-126 down-regulates VEGFA, inhibits
growth, and reduces average tumour weight. Mouse model of lung adenocarcinoma showed
that miR-200 family possess anti-metastatic abilities [5]. miR-125b-1 is located on a fragile site
on chromosome 11q24 which is deleted in a subset of patients with lung cancer [61].
Human brain cancer
The phrase “brain tumours” describes an inhomogeneous collection of various tumours of the
brain, which represents primary tumours of nervous central system or metastases. Glioblas‐
tomas (belongs to family of gliomas) are the most frequent occurrence and malignant form of
primary brain tumors in contrary to medulloblastomas, which have a better prognosis [2,11].
Several articles have described the effects of ectopic miRNA modulation on medulloblastoma
cell proliferation and growth.
Rescued expression of miR-9 and miR-125a were shown to promote medulloblastoma cell
growth arrest and apoptosis by targeting TrkC, whereas miR-29 has been shown to be down-
regulated in neuroblastoma and brain tumour [47,72]. Further, miR-34a induces apoptosis in
neuroblastoma cells, possibly by targeting the transcription factor E2F3 [11]. Transient
transfection in medullablastoma cells with miR-34a strongly inhibited cell proliferation, cell
cycle progression, cell survival and cell invasion. miR-34a was shown to inhibit c-Met, Notch-1,
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Notch-2 and CDK6. Ectopic up-regulation of miR-124 was shown to inhibit cell proliferation,
and it was demonstrated that miR-124 target and regulates CDK6. miR-125b, miR-324-5p, and
miR-326 over-expression inhibit medulloblastoma cell growth by targeting Hedgehog signal‐
ling pathway. miR-128 also inhibits growth by targeting Bmi-1 oncogene. Another miRNA,
miR-199b-5p negatively regulates proliferation and cell growth [72].
In contrary to medulloblastomas, are gliomas the most common and deadly primary human
brain tumours, and its subtype glioblastomas are highly invasive, very aggressive, and one of
the most incurable [2]. miR-181a, miR-181b and miR-181c were originally identified as down-
regulated in glioblastoma cells and tumours when compared to normal brain controls.
miR-181a and to a greater extent miR-181b were subsequently described as tumour suppressors
that inhibit growth and induce apoptosis of glioma cells. miR-181a over-expression down-
regulates Bcl-2. Several other miRNAs have been implicated in glioma malignancy as tumour
suppressors. miR-15b was suggested to target CCNE1, the gene encoding cyclin E1, however,
a direct link between CCNE1 down-regulation by miR-15 and cell cycle regulation was not
demonstrated. miR-146b was shown to inhibit glioma cell migration and invasion, and was
identified as one of miRNAs that is significantly deregulated in human glioblastoma tissue.
miR-146b over-expression or knock-down did not affect the growth of human glioblastoma
cell line, while it significantly reduced the migration and invasion of one glioblastoma cell line.
MMP16 was identified as one of the downstream targets of miR-146b. miR-125b was shown to
induce cell cycle arrest and inhibits CDK6 and CDC25A expression in glioma cell lines.
However, another study suggested oncogene function for miR-125b. miR-153 decrease cell
proliferation and increased apoptosis (pro-apoptotic miRNA), it inhibited Bcl-2 and Mcl-1.
miR-17 and miR-184 were identified as two miRNAs with reduced expression in higher grades
of glioblastomas. Their over-expression inhibited viability, proliferation, invasion and
decreased expression of AKT 2 and several other genes. let-7 over-expression effect was
investigated in glioma cells, its transfection reduced expression of RAS oncogenes, prolifera‐
tion in vitro, migration of the cells, and reduced the size of tumours generated [73].
Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and neck tumours are a heterogenous group with different behaviour at the various sites
arising from anatomical factors, cell-type variation, and differences in exposure to risk factors
including tobacco, alchocol, and viruses [74]. Head and neck squamous cell carcinoma is
represented by epithelial cancers of the oral cavity, pharynx, nasal cavity, paranasal sinuses,
salivary glands and larynx [75]. Studies were made in expression profiling regarding different
sites of head and neck tumours, tongue, tonsil, larynx, hypopharynx, nasopharynx, saliva, oral
cavity, salivary gland and animal models. Several miRNAs were identified as down-regulated,
and for some of their target genes were validated [74].
Low expression of miR-205 is significantly associated with local-regional recurrence inde‐
pendent of disease severity at diagnosis and treatment. Combined low expression of let-7d and
miR-205 is significantly associated with poor survival. In nasopharengyal carcinoma down-
regulation of miR-34 family, miR-145 and miR-143 was also observed [47]. Tumour suppressive
role in HNSCC has been suggested for let-7 family, miR-125a/b, miR-200, miR-133a/b, and
miR-100 [75]. General down-regulation of miR-1, miR-133a and let-7b was also observed [74].
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Reduced expression for majority of members of the let-7 family (except let-7i) was observed in
HNSCC. KRAS and HMGA2 have been characterized as targets for let-7 [75]. Notable among
down-regulated was also miR-98. However, another group identified miR-98 as another
regulator of an oncogene HMGA2 [74]. A possible molecular mechanism of miR-125a/b down-
regulation might be through targeting ERBB2, since its higher level of expression was observed
in oral SCC. Other target were also suggested for miR-125, namely KLF13, CXCL11 and FOXA1
[74,75]. Down-regulation of miR-133a/b in primary HNSCC may further contribute to increased
cell proliferation and decreased apoptosis. PKM2 has been validated as cellular target for both,
miR-133a and miR-133b, and increased expression of PKM2 has been associated with cancer
progression. Finally, miR-100 has been observed at suppressed levels in primary HNSCC and
derived cell lines. A few of its targets are known, namely FGFR1, MMP13, ID1, FGFR3, EGR2.
The exact role has to be investigated yet, but suggestion has been made that down-regulation
of miR-100 means higher rate of cell proliferations.
Deregulation of miRNAs in cancer can occur through epigenetic changes (promoter CpG
island hyper-methylation in the case of miR-200 family) [8]. Suppressed miR-200a was detected
in primary oral SCC. Members of miR-200 family inhibit EMT by directly targeting ZEB1/ZEB2,
suppressed levels of miR-200a may promote EMT. At last, it was observed that miR-137 and
miR-193a could be also silenced via hyper-methylation, CDK6 and E2F6 has been suggested
as their major targets. It was also shown that miR-137 hyper-methylation is associated with
poorer average survival [74,75].
Urological tumours
Renal  cell  carcinoma (RCC).  The VHL tumour suppressor  signalling pathway is  the most
important deregulated pathway in clear cell  RCC, the dominant subtype of  kidney can‐
cers. The VHL gene can be spontaneously deleted or hyper-methylated. The regulation of
the VHL pathway by miRNAs has not been well studied in RCC. The interactions have
been proposed but a direct relation between miRNAs and VHL or HIF1A were not pro‐
ven. A subset of miRNAs has been identified as regulated by VHL pathway, 3 miRNAs
were up-regulated and 6 were down-regulated. The second commonly deregulated path‐
way is VEGF signalling pathway, which is transcriptionally regulated by HIF (after hypo‐
xia)  or  due to  loss  of  VHL.  Interaction between miRNAs and VEGF has  not  been well
studied in RC, and only miR-29b  has been shown to indirectly regulate VEGF. However,
strong inverse  correlation between miR-200  family  and VEGFA has  been observed with
suggestion that VEGFA is direct target of these miRNAs [76]. Down-regulation of miR-141
was found in malignant compared to matched non-malignant tissue samples [47].
Bladder cancer.  Mutation or over-expression of the FGFR3 gene occurs in approx. 80 % of
all patients with low-grade non-invasive urothelial carcinomas. Some well-established de‐
regulated  miRNAs  in  bladder  cancer  are  predicted  to  target  FGFR3,  and  regulation  of
FGFR3 by miR-99  and miR-100  of  four predicted miRNAs has been experimentally vali‐
dated. Family miR-200 is associated with an epithelial phenotype; its ectopic expression in
bladder cancer cell lines induces up-regulation of epithelial and down-regulation of mes‐
enchymal markers. Up-regulation of miR-143 is accompanied by down-regulation of RAS
[76].  Transfection of  bladder cancer  cell  lines  with pre-miR-129  exerts  significant  growth
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inhibition and induces cell death. mir-129  is shown to target GALNT1 and SOX4. Trans‐
fection of miR-30-3p, miR-133a and miR-199a* results in decrease of tumour cell growth in
bladder cancer. miR-101 inhibits cell proliferation in bladder transitional cell carcinoma by
targeting EZH2 and altering global  chromatin  structure.  Down-regulation of  miR-145  in
bladder cancer has been also observed [47].
Prostate cancer. A major signal transduction pathway in prostate cancer is PI3K/Akt signalling
pathway that is hyper-activated in approx. 30-50 % of prostate cancer. Many of the predicted
miRNAs that are predicted to target proteins of this pathway are differentially regulated in
prostate cancer. Second pathway is androgen receptor (AR) pathway. miR-125b is an androgen-
sensitive miRNA, which has been shown to regulate apoptosis through inhibition of BAK1.
miR-101 has been shown to be up-regulated in human prostate cancer and it seems that through
inhibition of EZH2 reduce invasion and induce morphological changes in prostate cancer cells
[76]. miR-221 is found to be progressively down-regulated in aggressive forms of prostate
cancer. Down-regulation of miR-221 is linked to cancer progression and recurrence in a high
risk prostate cohort. Progressive miR-221 down-regulation also hallmarks metastasis [47,76].
miR-499a has been shown to be down-regulated in prostate cancer tissue. Its introduction into
prostate cancer cells results in cell cycle arrest and apoptosis, where it regulates cell growth
and viability in part by repressing the expression of HDAC1 [47]. miR-15a-miR-16-1 cluster,
located at chromosome 13q14, is deleted in most cases of prostate cancer [21].
Melanomas
Melanoma is the most aggressive type of skin cancer, and it is resistant to therapy in its
advanced stages  [77].  Abnormalities  in  several  signal  transduction pathways,  which are
important for normal melanocyte development, only partly explain molecular mechanism
directly linking UV radiation to the development of melanoma. miRNAs are emerging as
important causal factors to melanoma initiation and progression [78].  In 45 primary cul‐
tured melanoma cell  lines,  there was observed that  many genomic loci  containing miR‐
NAs  are  frequently  affected  (85.9  %)  by  copy  number  abnormalities.  For  an  example,
copy number losses of the region containing miR-218-1 and SLIT2 were shown in 33 % of
all  investigated  melanoma  lines  [79].  Proteins  involved  in  miRNA  biogenesis,  Drosha,
Dicer and Ago, are over-expressed in melanoma [32].
However, deregulation of miRNAs expression is not always explained. let-7  plays a role
in melanoma development and progression, its targets are many cancer-promoting mole‐
cules, such as NRAS, Raf, c-myc, cyclin D1/D3, and CDK4 [77]. Analyzing 10 melanocytic
nevi  and 10  primary  melanomas,  it  was  revealed  that  five  members  of  the  let-7  family
were significantly down-regulated in melanoma [80]. Over-expression of let-7b leads to in‐
hibition of cell cycle progression and inhibition of its targets (cyclin D1/D3/A and CDK4)
[77]. A direct interaction of let-7b with the cyclin D1 3'-UTR was showed. Let-7a was thus
demonstrated to regulate expression of integrin beta3 and RAS oncogene, which is highly
related to melanoma progression.
Another family, miR-34, has tumour suppressive role. Expression of miR-34a is silenced due
to an aberrant CpG methylation in 43.2 % of melanoma cell lines and in 62.5 % of primary
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melanoma samples. The tumour suppressive function of miR-34a has not yet been investigated,
however, there was shown a reduced expression of miR-34b/c and miR-199a* and it was
proposed that their target is MET oncogene [80]. Another miRNA with potentially tumour
suppressor role is embedded in CpG island and epigenetically regulated in melanoma, this is
miR-370 [79].
miR-203 has also an important tumours suppressor role in a lot of cancers, and it is often lost
due to deletion or due to promoter CpG hyper-methylation. miR-203 target p63, and their
relationship might be relevant also in melanoma, since it is known that miR-203 functions as
switch between epidermal proliferation and differentiation [81].
Gynaecological tumours
miR-125b-1 is located on a fragile site on chromosome 11q24 which is deleted in a subset of
patients with ovarian and cervical cancer [61].
Cervical cancer. Cervical cancer aetiology is strongly linked to HPV infection, and involvement
of virus protein E6 and E7 in pathogenesis is well established. The exact pathway from infection
to tumorigenesis has not been elucidated yet. However, down-regulation was observed for:
let-7b/c, miR-23b, miR-196b, miR-143, and miR-145. miR-143 and miR-145 were equally down-
regulated in all cell lines of cervical cancer (HPV infected and HPV not infected), whereas
miR-218 was the unique miRNA down regulated only in HPV-16 and HPV-18 positive cell
lines. Down-regulation of miR-214 is related to the ability of this miRNA to inhibit HeLa cells
proliferation through targeting MEK3 and JNK1 transcripts. HPV protein E6 induces destabi‐
lization of p53, down-regulation of miR-34a and increased proliferation of pre-malignant HPV
infected cervical cancer cell lines [82].
Endometrial cancer. Reciprocal association between down-regulation of miR-192-2 and SOX4
expression was determined; it was further established that restoration of miR-192-2 induced a
decrease in SOX4 expression and this resulted in diminished cell proliferation. Decreased
expression for miR-152 and miR-101 was found to consist of an independent risk factor for
disease free survival. Restoration of those miRNAs by transfection in cell lines lead to dimin‐
ished cell proliferation. Down-regulation of miR-101 was correlated with strong positive
immunoreactivity of COX2, which was previously shown to be associated with worse
prognosis. To date, no data are available for relationship between miRNAs and oestrogen
response in endometrial cancer [82].
Ovarian cancer. Inconsistencies are observed between results in ovarian cancer studies for well-
known tumour suppressors. These could be due to the differences in study populations and
methodologies used, due to the choice of control group and type of control. For instance, the
number of studies used as control cell lines and another number of studies used whole normal
ovaries. The existence of significant discrepancies in expression profiles of certain miRNAs
indicate the need of further and more in-depth research that would establish those results [82].
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5.2. lncRNAs as tumour suppressors
lncRNAs are known to mediate epigenetic modifications of DNA by recruiting chromatin
complexes to specific loci [8]. Only a handful of lncRNAs have been characterized, and their
involvement in control of gene expression [3]. We therefore presented four lncRNAs with
proposed tumour suppressor function in cancer.
MEG3
MEG3, located in chromosome 14q32, is maternally expressed imprinted gene, which repre‐
sents lncRNA, but also hosted miRNAs and snoRNAs. It plays role in cell proliferation, and
its expression is under epigenetic control. MEG3 and its hosted miRNAs and snoRNA could
represent a tumour suppressor gene, since aberrant CpG methylation (promoter hyper-
methylation, and hyper-methylation of the intergenic region) has been observed in several
types of cancer, as well as their gene copy number loss [9].
MEG3 ncRNA might modulate binding of p53 on the promoter of its target genes [9]. It was
later verified that MEG3 was associated with p53 and that this association was required for
p53 activation, further suggesting tumour suppressor role for MEG3. It was demonstrated that
MEG3 expression is markedly decreased in glioma tissues compared to adjunct normal tissues.
Ectopic expression of MEG3 inhibited cell proliferation and promoted cell apoptosis in glioma
cell lines [83]. Growth inhibition is partially due to apoptosis induced by MEG3, which induces
accumulation of p53, stimulates transcription from p53-dependent promoter and regulates p53
target gene expression. Loss or significantly reduction of MEG3 expression has been further
found in other cancer cell lines examined, bladder, bone marrow, breast, cervix, colon, liver,
lung, meninges, and prostate, as well as in other primary tumours, neuroblastoma, hepato‐
cellular carcinoma, and meningioma. It has been suggested that DNA methylation plays a
major role in silencing the MEG3 gene in tumours [84].
GAS5
LncRNA GAS5 is highly expressed in cells that have arrested growth and can sensitize a cell
to apoptosis by regulating activity of glucocorticoids in response to nutrient starvation. It has
been linked with breast cancer. GAS5 transcript levels are significantly reduced compared to
un-affected normal breast epithelia, suggesting that could act as tumour suppressor. GAS5
maintain sufficient caspase activity to activate appropriate apoptotic response in diseased cells.
Chromosomal translocation affecting 1q25 locus that contains the GAS5 gene has been detected
in melanoma, B-cell lymphoma, prostate and breast cancer [7,85]. GAS5 regulates expression
of a critical subset of genes with tumour suppressive consequences [4].
LincRNA-21
LincRNA-p21 is required for the global repression of genes that interfere with p53 function
regulating cellular apoptosis; it physically interacts with a protein hnRNP-K, allows it
localization to promoters of genes that need to be repressed in a p53-dependent manner [4].
In response to DNA damage, lncRNAs are induced by the p53 tumour suppressor pathway.
lincRNA-p21 plays an important role in cellular response to apoptotic signal, it is induced by
p53 and act as an inhibitor of the p53-dependent transcriptional response by repressing the
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transcription of genes that interfere with apoptosis (guidance of hnRNP-K to the promoters of
genes repressed by p53). LincRNA-p21 has not been directly associated with disease yet, but
loss of function of lincRNA-p21 might be involved in cancer initiation since functions to trigger
cell death through the induction of apoptosis program [7,9,85].
CCND1
It is involved in the regulation of Cyclin D1 gene expression. Cyclin D1 is a cell cycle regulator
often mutated, amplified and over-expressed in various types of cancer. After binding of this
lncRNA on RNA-binding protein, consequently inhibition of enzymatic activities of the
histone acetyltransferases occurs, leading to silencing of cyclin D1 gene. These studies suggest
that this lncRNA is a tumour suppressor RNA, which can be rapidly induced by cellular stress
to regulate it sense gene expression [85].
6. Conclusion
The rest of ncRNAs, other than miRNAs, in regulation biological functions are more or less
unexplored, and this should be further investigated in future research. Regarding therapeutic
approaches, we still need more knowledge concerning which miRNAs to target, how to
produce and stabilize them, how to direct them to the target tissue. The specificity of drug-like
oligonucleotides is important, because of the off-target effect. The off-target effect is also a
significant challenge, especially considering that miRNA-mediated repression often requires
a homology of only six to seven nucleotides in the seed region of the miRNA and mRNA target
site. Toxicity due to chemical modifications, which is used to facilitate cellular uptake and
prevent degradation, should be take into account. However, only recently was described the
possibility of using exososmes and exosomal tumour-suppressive miRNAs as novel cancer
therapy [86].
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